Literature DB >> 26376994

Role of Adjuvant Radiotherapy in Left-Sided Pancreatic Cancer-Population-Based Analysis with Propensity Score Matching.

Yu Jin Lim1, Kyubo Kim2, Eui Kyu Chie1,3, BoKyong Kim1, Sung W Ha1,3.   

Abstract

This population-based study evaluated the survival impact of postoperative radiotherapy (PORT) in left-sided pancreatic cancer. The Surveillance, Epidemiology, and End Results (SEER) database was used to identify patients with surgically resected left-sided pancreatic adenocarcinoma from 2004 to 2010. Propensity score matching was conducted to compare PORT and non-PORT groups. A total of 445 patients were identified, and PORT was performed in 180 (40 %) patients. In the unmatched population, there were no significant differences in overall survival (OS) (P = 0.197) and cause-specific survival (CSS) (P = 0.379) between the PORT and non-PORT groups. After propensity score matching, the patients treated with PORT had longer median OS (P = 0.012) and CSS (P = 0.039) than the non-PORT group. In propensity-adjusted multivariate analysis, non-receipt of PORT was a poor prognostic factor in OS (hazard ratio [HR] 1.39, 95 % confidence interval [CI] 1.08-1.79), and CSS (HR 1.31, 95 % CI 1.01-1.71). The log odds of positive lymph nodes (LOODS) (≥-0.73) was also associated with worse OS (P = 0.003) and CSS (P = 0.001). In left-sided pancreatic cancer, considering the addition of PORT is a reasonable option as in pancreatic head cancer. The LOODS was suggested as a strong predictive indicator of the patients' prognoses.

Entities:  

Keywords:  Adjuvant radiotherapy; Left-sided pancreas; Pancreatic cancer; SEER; Survival

Mesh:

Year:  2015        PMID: 26376994     DOI: 10.1007/s11605-015-2941-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  28 in total

1.  Log odds of positive lymph nodes: a novel prognostic indicator superior to the number-based and the ratio-based N category for gastric cancer patients with R0 resection.

Authors:  Zhe Sun; Yan Xu; De Ming Li; Zhen Ning Wang; Guo Lian Zhu; Bao Jun Huang; Kai Li; Hui Mian Xu
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

Review 2.  Indications for propensity scores and review of their use in pharmacoepidemiology.

Authors:  Robert J Glynn; Sebastian Schneeweiss; Til Stürmer
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-03       Impact factor: 4.080

3.  Prognostic assessment of different lymph node staging methods for pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds of positive lymph nodes.

Authors:  Marco La Torre; Giuseppe Nigri; Niccolò Petrucciani; Marco Cavallini; Paolo Aurello; Giulia Cosenza; Genoveffa Balducci; Vincenzo Ziparo; Giovanni Ramacciato
Journal:  Pancreatology       Date:  2014-06-14       Impact factor: 3.996

4.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

5.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

6.  Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas.

Authors:  Kristin J Redmond; Christopher L Wolfgang; Elizabeth A Sugar; Julia Ahn; Hari Nathan; Daniel Laheru; Barish H Edil; Michael A Choti; Timothy M Pawlik; Ralph H Hruban; John L Cameron; Joseph M Herman
Journal:  Ann Surg Oncol       Date:  2010-08-03       Impact factor: 5.344

7.  A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma.

Authors:  Theodore P McDade; Joshua S Hill; Jessica P Simons; Bilal Piperdi; Sing Chau Ng; Zheng Zhou; Sidney P Kadish; Thomas J Fitzgerald; Jennifer F Tseng
Journal:  Cancer       Date:  2010-07-01       Impact factor: 6.860

8.  Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data.

Authors:  Lisa Hazard; Jonathan D Tward; Aniko Szabo; Dennis C Shrieve
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

Review 9.  The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models.

Authors:  Qi Ling; Xiao Xu; Shu-Sen Zheng; Holger Kalthoff
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2013-10

10.  Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer.

Authors:  Alessio G Morganti; Massimo Falconi; Ruud G P M van Stiphout; Gian-Carlo Mattiucci; Sergio Alfieri; Felipe A Calvo; Jean-Bernard Dubois; Gerd Fastner; Joseph M Herman; Bert W Maidment; Robert C Miller; William F Regine; Michele Reni; Navesh K Sharma; Edy Ippolito; Vincenzo Valentini
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-09-11       Impact factor: 7.038

View more
  2 in total

1.  Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment.

Authors:  Sebastian Bachmayer; Gerd Fastner; Andrea Vaszi; Wolfgang Iglseder; Peter Kopp; Josef Holzinger; Adam Dinnewitzer; Gabriel Rinnerthaler; Simon Peter Gampenrieder; Klaus Emmanuel; Richard Greil; Felix Sedlmayer; Franz Zehentmayr
Journal:  Strahlenther Onkol       Date:  2018-03-01       Impact factor: 3.621

2.  The role of radiotherapy for pancreatic malignancies: a population-based analysis of the SEER database.

Authors:  Y Luo
Journal:  Clin Transl Oncol       Date:  2021-07-04       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.